Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.70 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.60 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497371 | 0.97 | KEAP1 (0.73) | KEAP1FFAR1ALDH1A1TDP1TRPA1 | |
| SCHEMBL712597 | 0.95 | KEAP1 (0.70) | KEAP1FFAR1ALDH1A1TDP1TRPA1 | |
| SCHEMBL5355399 | 0.89 | KEAP1 (0.75) | KEAP1FFAR1ALDH1A1TDP1TRPA1 | |
| SCHEMBL19561359 | 0.89 | HDAC1 (0.69) | KEAP1FFAR1ALDH1A1TDP1TRPA1 | |
| SCHEMBL31596300 | 0.89 | TDP1 (0.76) | KEAP1FFAR1ALDH1A1TDP1TRPA1 | |
| SCHEMBL26624571 | 0.89 | KEAP1 (0.61) | KEAP1FFAR1ALDH1A1TDP1TRPA1 | |
| SCHEMBL5598977 | 0.88 | KEAP1 (0.67) | KEAP1FFAR1ALDH1A1TDP1TRPA1 | |
| SCHEMBL19625551 | 0.87 | MAPT (0.68) | KEAP1FFAR1ALDH1A1TDP1TRPA1 | |
| SCHEMBL9705008 | 0.87 | KEAP1 (0.59) | KEAP1FFAR1ALDH1A1TDP1TRPA1 | |
| SCHEMBL4198137 | 0.87 | KEAP1 (0.59) | KEAP1FFAR1ALDH1A1TDP1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025119663-A1 | HERBICIDAL DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2025-06-12 | — | — | WO | disclosed |
| US-20200339577-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-29 | — | — | US | disclosed |
| US-10745397-B2 | 1-Substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-18 | — | — | US | disclosed |
| EP-3325490-B1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2019-12-18 | — | — | EP | disclosed |
| US-20180215754-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-02 | — | — | US | disclosed |
| EP-3325490-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017014323-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-26 | — | — | WO | disclosed |
| WO-2016088903-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016021742-A1 | HETEROCYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-11 | — | — | WO | disclosed |
| CN-104327117-A | 1-(2-arylindenyl) dicyclohexylphosphine and preparation method and application thereof | UNIV HUAZHONG NORMAL | 2015-02-04 | — | — | CN | disclosed |
| EP-1478463-A1 | PROCESS FOR THE CARBONYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND AND CATALYST THEREFORE | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 2004-11-24 | — | — | EP | disclosed |
| EP-1476417-A1 | PROCESSES FOR THE PREPARATION OF A CAROBXYLIC ANHYDRIDE AND USE OF THE CARBOXYLIC ANHYDRIDE AS AN ACYLATION AGENT | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 2004-11-17 | — | — | EP | disclosed |
| US-20040152715-A1 | Cycloalkylene amide compounds as NR2B receptor antagonists | KAWAI MAKOTO (JP) | 2004-08-05 | — | — | US | disclosed |
| WO-2004054579-A1 | 2-PYRIDYL AND 2-PYRIMIDYL CYCLOALKYLENE AMIDE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2004-07-01 | — | — | WO | disclosed |
| WO-2003070370-A1 | PROCESS FOR THE CARBONYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND AND CATALYST THEREFORE | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003070679-A1 | PROCESSES FOR THE PREPARATION OF A CAROBXYLIC ANHYDRIDE AND USE OF THE CARBOXYLIC ANHYDRIDE AS AN ACYLATION AGENT | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2003-08-28 | — | — | WO | disclosed |
| EP-1105366-A1 | DIVINYLSTILBENESULFONIC ACID DERIVATIVES | Ciba SC Holding AG (CH) | 2001-06-13 | — | — | EP | disclosed |
| WO-2001010854-A1 | BENZOTHIAZOLE COMPOUNDS AND THEIR USE AS OPTICAL BRIGHTENERS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2001-02-15 | — | — | WO | disclosed |
| WO-2000009471-A1 | DIVINYLSTILBENESULFONIC ACID DERIVATIVES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2000-02-24 | — | — | WO | disclosed |
| CN-1241188-A | Heterocyclylmethyl-substed pyrazol derivs. | BAYER AG (DE) | 2000-01-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745397-B2 | 1-Substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4 receptor antagonists | PTGER4, PTGER1, PTGER3 | KEAP1 1571/4885FFAR1 275/4885ALDH1A1 718/4885 |
| US-20200339577-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | KEAP1 1571/4885FFAR1 275/4885ALDH1A1 718/4885 |
| US-20180215754-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | KEAP1 1571/4885FFAR1 275/4885ALDH1A1 718/4885 |
| US-20040152715-A1 | Cycloalkylene amide compounds as NR2B receptor antagonists | GRIN1, GRIN3A, GRIN2A | KEAP1 2526/4885FFAR1 135/4885ALDH1A1 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.